Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history. | | | | Across the nation, a third of state Medicaid programs paid for GLP-1 drugs for weight loss as of mid-2025. That number has shrunk this year. (John Karsten Moran/For The Washington Post) | | | | | | |  What to know Massachusetts and other states have cut Medicaid coverage for GLP-1 weight-loss drugs, affecting low-income patients who can't afford them. This decision highlights disparities in obesity treatment access, as wealthier individuals can still afford the drugs. The cuts are attributed to high costs, with states like Michigan and Rhode Island also limiting coverage. Summary is AI-generated, newsroom-reviewed. | | | | | How was today's newsletter? | | | | | | | | |
Have a question? Ask the Post AI to learn more 
